Portal Hypertension Management Global Market Report 2024

Portal hypertension management encompasses strategies aimed at treating and preventing complications arising from elevated pressure in the portal vein system, often associated with liver cirrhosis. These measures include lifestyle adjustments, medication administration (such as beta-blockers), and procedures such as variceal banding to prevent or treat complications such as variceal bleeding and ascites.

The primary approaches to portal hypertension management include medication, non-surgical procedures, and surgery. Medication for portal hypertension typically includes nonselective beta-blockers, vasoconstrictors, diuretics, and antibiotics, which are used to manage conditions such as variceal bleeding, ascites, and bacterial infections in patients with increased portal pressure. Non-surgical procedures involve techniques such as transjugular intrahepatic portosystemic shunt (TIPS), which is employed across various healthcare settings including hospitals, specialty clinics, and others.

The portal hypertension management research report is one of a series of new reports that provides portal hypertension management market statistics, including the portal hypertension management industry's global market size, regional shares, competitors with a portal hypertension management market share, detailed portal hypertension management market segments, market trends and opportunities, and any further data you may need to thrive in the portal hypertension management industry. This portal hypertension management market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The portal hypertension management market size has grown strongly in recent years. It will grow from $2.88 billion in 2023 to $3.07 billion in 2024 at a compound annual growth rate (CAGR) of 6.5%. Historical growth can be attributed to several factors including the rising prevalence of liver diseases, growth in the geriatric population, increased awareness and screening programs, economic burden associated with liver diseases, approvals of new drugs and therapies, and advancements in diagnostic methods.

The portal hypertension management market size is expected to see strong growth in the next few years. It will grow to $3.97 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. Anticipated growth in the forecast period can be attributed to several key factors, increased investments in healthcare infrastructure, expanded health insurance coverage, favorable regulatory environments with accelerated approval processes, ongoing research and development activities aimed at understanding the pathophysiology of portal hypertension, and advancements in remote monitoring technologies enabling continuous patient management. Major trends expected in the forecast period include the widespread adoption of telemedicine, ongoing advancements in medical technology such as bio-engineered liver tissue, expansion in personalized medicine with the development of targeted therapies tailored to individual patient profiles, and enhancements in diagnostic methods including non-invasive imaging technologies such as elastography.

The portal hypertension management market is poised for growth due to an increasing prevalence of liver diseases such as hepatitis. Liver diseases encompass a spectrum of conditions affecting liver structure and function, often resulting in symptoms such as jaundice, fatigue, and abdominal pain. Causes include viral infections, alcohol abuse, and metabolic disorders. Management of portal hypertension in liver disease aims to alleviate complications such as variceal bleeding, ascites, and hepatic encephalopathy by reducing pressure in the portal vein system, thereby improving patient outcomes. For example, in 2022, Cancer Australia reported approximately 2,905 new cases of liver cancer diagnosed in Australia, underscoring the rising incidence contributing to market growth.

Leading companies in the portal hypertension management sector are advancing minimally invasive devices to enhance treatment efficacy and minimize procedural risks. These devices are designed to perform procedures with minimal disruption to tissues, typically through small incisions or natural body openings. For instance, Medtronic Plc received FDA approval in November 2023 for the Symplicity Spyral renal denervation system, utilizing radiofrequency energy to manage hypertension by targeting nerves near the kidneys.

In February 2023, AstraZeneca Plc acquired CinCor Pharma Inc. for $1.8 billion. This acquisition enriches AstraZeneca's portfolio with CinCor's barostat (CIN-107), an aldosterone synthase inhibitor designed to lower blood pressure in treatment-resistant hypertension. CinCor Pharma Inc., based in the US, specializes in developing innovative medications for hypertension management.

Major companies operating in the portal hypertension management market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Merck & Co., Boehringer Ingelheim International GmbH, Amneal Pharmaceuticals LLC., Lupin Ltd., Daiichi Sankyo, Dr. Falk Pharma GmbH, Cumberland Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Chiasma Inc., Debiovision Inc.

North America was the largest region in the portal hypertension management market in 2023. The regions covered in the portal hypertension management market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the portal hypertension management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The portal hypertension management market consists of revenues earned by entities by provide services such as medical management, endoscopic therapy, interventional radiology procedures, and monitoring and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The portal hypertension management market also includes sales of nonselective beta-blockers, and vasoconstrictors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.